Dr Wungki Park, from Memorial Sloan Kettering Cancer Center in the US and who is involved in the trial, said the results were extremely encouraging so far. "We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," he said. Daraxonrasib is a KRAS inhibitor treatment that has already been approved in the US.

It works by locking on to and shutting off certain mutations, called RAS, external, found in most pancreatic cancers that drive tumour growth.Dozens of other cancers, including lung and ovarian, can have similar mutations, meaning the drug might help lots of other patients too. Dr Godfrey said: "I would hope that the early success that we are beginning to see in pancreatic cancer can also be rolled out to other cancers."He said longer trials and results were vital. "Cancer can come back and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed."Prof Elena Garralda, chair of a European cancer conference called EORTC where the work is being presented to other doctors, said: "These results are exciting because they show the combined treatment could potentially significantly improve patients' overall survival, as well as the time before tumours start to grow again."There are 11,500 diagnoses of the disease in Britain each year and around 10,200 deaths, according to Cancer Research UK.

Actor Alan Rickman died of the disease in 2016, five months after diagnosis.Symptoms can include, external jaundice, itchy skin, darker pee, paler poo, unexplained weight loss, tiredness and high temperature.